Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Rani Therapeutics Holdings, Inc. (RANI)

Cellectis S.A. and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Cellectis S.A. and Rani Therapeutics Holdings, Inc. are of similar size ($84.6M and $79.9M). Rani Therapeutics Holdings, Inc. grew revenue faster over the last twelve months: 78.7% against 0.61%. Cellectis S.A. has the higher net margin (−102.3% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Rani Therapeutics Holdings, Inc. leads on 8 and Cellectis S.A. on 7.

Valuation

Metric CLLS RANI Biotechnology median
P/E n/m n/m 10.26
P/S 1.59 19.28 9.18
P/B 2.48 2.03 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 0.13 11.82 8.98
Earnings yield (64.76%) (51.92%) (34.89%)
Free cash flow yield (45.45%) (20.90%) (24.52%)

Profitability

Metric CLLS RANI Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (90.88%) (652.78%) 0.00%
Net margin (102.34%) (596.97%) 0.00%
Free cash flow margin (68.63%) (402.83%) 0.00%
Return on equity (94.54%) (155.24%) (50.12%)
Return on assets (21.02%) (77.54%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS RANI Biotechnology median
Revenue growth (TTM) 0.61% 78.73% 6.26%
EPS growth (last fiscal year) (63.41%) 57.14% 29.88%
Revenue growth, 5-year CAGR (0.70%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS RANI Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 5.31 4.89
Net debt to EBITDA 9.54 1.33 1.01

Dividend

Metric CLLS RANI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CLLS RANI Biotechnology median
Market cap 84.63m 79.85m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack